FNY Investment Advisers’s NextCure NXTC Stock Holding History

FNY Investment Advisers’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,000	Closed	-$132K	–	685
2022 Q3	$132K	Buy	+4,000	New	+$204K	0.09%	127

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FNY Investment Advisers's NXTC Position: Q4 2022 in Review

FNY Investment Advisers sold out of NextCure (NXTC) in Q4 2022, closing a stake of 4,000 shares — an estimated $132K sold.

FNY Investment Advisers first reported a position in NXTC in Q3 2022 and held it in 1 quarter. The position peaked at $132K in Q3 2022. 45 funds tracked by Wall St. Rank hold NXTC as of Q4 2022.

FNY Investment Advisers reported no remaining NextCure position as of Q4 2022 after selling out during the quarter.
FNY Investment Advisers sold 4,000 NextCure shares in Q4 2022, an estimated $132K.
FNY Investment Advisers first reported a position in NextCure in Q3 2022 and held it in 1 quarter.
FNY Investment Advisers's NextCure position peaked at $132K in Q3 2022.
45 funds tracked by Wall St. Rank held NextCure as of Q4 2022.

Based on FNY Investment Advisers's 13F filing for Q4 2022, filed 10 Jan 2023.